# Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

> **NCT04056949** · PHASE2 · UNKNOWN · sponsor: **Junling Li** · enrollment: 30 (estimated)

## Conditions studied

- Extensive-Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel/Albumin-Bound Paclitaxel
- **DRUG:** IBI308

## Key facts

- **NCT ID:** NCT04056949
- **Lead sponsor:** Junling Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-05
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056949, "Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04056949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*